[HTML][HTML] A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook
A Kramvis, KM Chang, M Dandri, P Farci… - Nature Reviews …, 2022 - nature.com
Globally, 296 million people are infected with hepatitis B virus (HBV), and approximately one
million people die annually from HBV-related causes, including liver cancer. Although there …
million people die annually from HBV-related causes, including liver cancer. Although there …
Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the …
V Mallet, F van Bömmel, C Doerig… - The Lancet infectious …, 2016 - thelancet.com
Viral hepatitis affects millions of people worldwide, and host immunity is the key determinant
of patient outcome. Viral hepatitis can be life threatening in patients with haematological …
of patient outcome. Viral hepatitis can be life threatening in patients with haematological …
[PDF][PDF] Long‐term efficacy of tenofovir monotherapy for hepatitis B virus‐monoinfected patients after failure of nucleoside/nucleotide analogues
F van Bömmel, RA de Man, H Wedemeyer… - …, 2010 - Wiley Online Library
Tenofovir disoproxil fumarate (TDF) has demonstrated high antiviral efficacy in treatment‐
naive patients with chronic hepatitis B virus (HBV) infection but experience in …
naive patients with chronic hepatitis B virus (HBV) infection but experience in …
A global scientific strategy to cure hepatitis B
PA Revill, FV Chisari, JM Block, M Dandri… - The lancet …, 2019 - thelancet.com
Chronic hepatitis B virus (HBV) infection is a global public health challenge on the same
scale as tuberculosis, HIV, and malaria. The International Coalition to Eliminate HBV (ICE …
scale as tuberculosis, HIV, and malaria. The International Coalition to Eliminate HBV (ICE …
[PDF][PDF] Comparison of adefovir and tenofovir in the treatment of lamivudine‐resistant hepatitis B virus infection
F van Bömmel, T Wünsche, S Mauss, P Reinke… - …, 2004 - Wiley Online Library
Adefovir dipivoxil was recently approved for the treatment of wild‐type and lamivudine‐
resistant hepatitis B virus (HBV) infection. Tenofovir disoproxil fumarate, a congender of …
resistant hepatitis B virus (HBV) infection. Tenofovir disoproxil fumarate, a congender of …
[PDF][PDF] Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors
F van Bömmel, A Bartens, A Mysickova… - …, 2015 - Wiley Online Library
Hepatitis B envelope antigen (HBeAg) seroconversion represents an endpoint of treatment
of chronic hepatitis B virus (HBV) infections. We have studied whether levels of serum HBV …
of chronic hepatitis B virus (HBV) infections. We have studied whether levels of serum HBV …
[PDF][PDF] Risks and Benefits of Discontinuation of Nucleos (t) ide Analogue Treatment: A Treatment Concept for Patients With HBeAg‐Negative Chronic Hepatitis B
F van Bömmel, T Berg - Hepatology Communications, 2021 - Wiley Online Library
Systematic discontinuation of long‐term treatment with nucleos (t) ide analogues (NAs) is
one strategy to increase functional cure rates in patients with chronic hepatitis B e antigen …
one strategy to increase functional cure rates in patients with chronic hepatitis B e antigen …
[PDF][PDF] Tenofovir for patients with lamivudine‐resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy
F van Bömmel, B Zöllner, C Sarrazin, U Spengler… - …, 2006 - Wiley Online Library
Incomplete virological response to adefovir dipivoxil (ADV) has been observed in patients
with lamivudine‐resistant hepatitis B virus (HBV) infection and may be associated with …
with lamivudine‐resistant hepatitis B virus (HBV) infection and may be associated with …
Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians
P Arends, MJ Sonneveld, R Zoutendijk, I Carey… - Gut, 2015 - gut.bmj.com
Background Hepatocellular carcinoma (HCC) risk-scores may predict HCC in Asian
entecavir (ETV)-treated patients. We aimed to study risk factors and performance of risk …
entecavir (ETV)-treated patients. We aimed to study risk factors and performance of risk …
[PDF][PDF] Candidate biomarkers for the diagnosis and prognosis of drug‐induced liver injury: an international collaborative effort
RJ Church, GA Kullak‐Ublick, J Aubrecht… - …, 2019 - Wiley Online Library
Current blood biomarkers are suboptimal in detecting drug‐induced liver injury (DILI) and
predicting its outcome. We sought to characterize the natural variabilty and performance …
predicting its outcome. We sought to characterize the natural variabilty and performance …